BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 34887861)

  • 21. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
    Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
    Front Immunol; 2021; 12():690056. PubMed ID: 34335594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer.
    Imai D; Yoshizumi T; Okano S; Itoh S; Ikegami T; Harada N; Aishima S; Oda Y; Maehara Y
    J Surg Res; 2019 Aug; 240():115-123. PubMed ID: 30927618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification.
    Takahashi D; Kojima M; Suzuki T; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Ikeda M; Nakatsura T; Ochiai A; Nagino M
    Sci Rep; 2018 Sep; 8(1):13166. PubMed ID: 30177687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer.
    Tahkola K; Ahtiainen M; Kellokumpu I; Mecklin JP; Laukkarinen J; Laakkonen J; Kenessey I; Jalkanen S; Salmi M; Böhm J
    Virchows Arch; 2021 Feb; 478(2):209-217. PubMed ID: 32676968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Impact of Immune Microenvironment on the Prognosis of Pancreatic Ductal Adenocarcinoma Based on Multi-Omics Analysis.
    Yang B; Zhou M; Wu Y; Ma Y; Tan Q; Yuan W; Ma J
    Front Immunol; 2021; 12():769047. PubMed ID: 34777388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ERAP2 Is Associated With Immune Infiltration and Predicts Favorable Prognosis in SqCLC.
    Yang Z; Tian H; Bie F; Xu J; Zhou Z; Yang J; Li R; Peng Y; Bai G; Tian Y; Chen Y; Liu L; Fan T; Xiao C; Zheng Y; Zheng B; Wang J; Li C; Gao S; He J
    Front Immunol; 2021; 12():788985. PubMed ID: 34992605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
    Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
    BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma.
    Chen QF; Li W; Wu PH; Shen LJ; Huang ZL
    World J Gastroenterol; 2019 Sep; 25(35):5266-5282. PubMed ID: 31558872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
    Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
    Front Immunol; 2021; 12():769425. PubMed ID: 34804059
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
    Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
    BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
    Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
    Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.
    Liu B; Fu T; He P; Du C; Xu K
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34143198
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
    Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
    Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
    Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
    Front Immunol; 2021; 12():730746. PubMed ID: 34630409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GTF2IRD1 overexpression promotes tumor progression and correlates with less CD8+ T cells infiltration in pancreatic cancer.
    Zhuang H; Zhang C; Hou B
    Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32936232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
    Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
    Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor-Infiltrating Immune Cells and PD-L1 as Prognostic Biomarkers in Primary Esophageal Small Cell Carcinoma.
    Wu X; Ke X; Ni Y; Kuang L; Zhang F; Lin Y; Lin W; Xiong X; Huang H; Lin X; Zhang H
    J Immunol Res; 2020; 2020():8884683. PubMed ID: 33457428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.